Autolus therapeutics to present three clinical data updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (all) patients at the 2024 european hematology association (eha) congress

London, june 14, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announces three abstracts to be presented at the european hematology association (eha) congress, june 13-16, 2024. “we are looking forward to presenting longer-term data from adult patients with r/r all treated with obe-cel in the felix study,” said dr. christian itin, chief executive officer of autolus.
ALL Ratings Summary
ALL Quant Ranking